ECDDATA & PERSPECTIVES

The facts behind
the financial picture.

Contact the desk ↗
SOURCE REVIEW / 15 NOV 2026 ↗

Home / stocks

JNJ

Johnson & Johnson

NYSE · Innovative medicines and medical technology · Health Care · 2026-09-27

Johnson & Johnson reports Innovative Medicine and MedTech. The latest quarterly results distinguish reported earnings from adjusted earnings after specified charges.

Q3 2026 · Period ended 2026-09-27 · Results released 2026-10-13
Latest released results located as of 2026-11-15. Most recent quarterly earnings results located in official disclosures at the review cutoff.

Reported financial & operating measures

Quarterly disclosures · USD amounts in millions unless stated otherwise · Fiscal periods differ by issuer

Selected company metrics with period, units and accounting basis
MeasureValueUnitPeriodBasis / precision
Sales25,399USD millionQ3 2026GAAP
Net earnings210USD millionQ3 2026GAAP
Diluted EPS0.09USD/shareQ3 2026GAAP
Adjusted net earnings6,339USD millionQ3 2026non-GAAP
Adjusted diluted EPS2.59USD/shareQ3 2026non-GAAP
Innovative Medicine sales16,757USD millionQ3 2026GAAP
MedTech sales8,642USD millionQ3 2026GAAP
U.S. sales14,959USD millionQ3 2026GAAP
International sales10,440USD millionQ3 2026GAAP

Source reviewed: 2026-11-15. Selected measures, not a full set of audited statements or live stock prices.

Sources

https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance